LB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity
LB Pharmaceuticals Inc LBRX
$37.28
▼ -1.61%
($-0.61)
⬇️ Below Yest. Low
🔥 High Short Interest
Open
$37.89
Prev Close
$37.89
Day Range
$36.98 – $38.13
52W Range
$13.36 – $50.16
Market Cap
$1.20B
Beta
1.64
EPS (TTM)
$-2.98
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2025-09-11 |
| Shares Out. | 28,680,000 |
| Website | lbpharma.us/ ↗ |
| Phone | 19174506581 |
| Employees | 27 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$51.6M |
| Free Cash Flow | -$85.1M |
| Total Assets | $361.7M |
| Total Liabilities | $29.3M |
| Equity | $332.3M |
About LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
LB Pharmaceuticals Inc is a publicly traded company under the ticker symbol LBRX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-09-01)